Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168694 · ClinicalTrials.gov registry record
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 606
- Enrollment target
NCT07168694 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 606 participants.
The verdict
NCT07168694 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 606 participants
- Enrollment target
Study Summary
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2024-09-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07168694
The ClinicalTrials.gov registry entry for NCT07168694 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07168694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07168694 about?
NCT07168694 is a clinical study titled "A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia". The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multipl...
What is the current status of trial NCT07168694?
This trial is currently completed. The enrollment target is 606 participants. The study started on 2024-04-16. Estimated completion is 2024-09-26.
Who is sponsoring clinical trial NCT07168694?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.